#immune-therapy

#immune-therapy

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

C4b-binding protein (C4BP) was identified as the missing cofactor that allows anti-phosphatidylethanolamine (aPE) antibodies to exert their damaging effects, linking them to thrombosis and pregnancy complications.

When mitochondria are exposed to tissue or blood, they lose the electrical gradient across their outer membrane. Mitochondria that lack such a gradient are recognized by a cell's internal machinery as damaged and quickly destroyed. The vast majority of previous studies involved injecting 'naked' mitochondria directly into the bloodstream or tissue sites, but the approach isn't very efficient, so researchers often have to use 'ridiculous' doses of mitochondria.

More than 17,500 patients are living on the waiting list at any given time for a liver transplant. Unfortunately, there aren't enough of the available, donated organs to go around, leading to a critical and frequently deadly backlog. Roughly 10% of the patients on that waiting list die each year while waiting for the prospect of a new organ.

Before treatment began, participants underwent neuroimaging. Instead of relying on a single modality, the researchers fused structural connectivity (how regions are physically wired) with functional connectivity (how regions co-activate at rest). The goal was not to throw every possible feature at a black box, but to learn a constrained pattern-what the authors call structure-function "covariation"-that carries the most predictive signal for outcome. In other words, the model tries to find the smallest set of connections that meaningfully forecasts symptom change.

Ferroptosis, a major mechanism of non-apoptotic programmed cell death, critically regulates the homeostasis and functionality of peripheral CD4+ and CD8+ T cells. Here we demonstrate that in mouse, resistance of T cells to ferroptosis depends critically on the composition of standard rodent diets, and that dietary effects on ferroptosis have a crucial role in regulation of T cell homeostasis and immune responses.

On Tuesday the American Cancer Society (ACS) released its annual report on cancer statistics in the U.S., and it offered a rare bit of good news: the proportion of people who were alive at least five years after a cancer diagnosis hit a record high. The report found that, among all cancer patients diagnosed between 2015 and 2021 in the U.S., the survival rate at the five-year mark relative to those who didn't have cancer was 70 percent.

We're living in a curious moment for the status of cancer diagnosis and treatment, within the United States. The overall rate of prevalence for diseases that fall under the wide, wide title of "cancers" is increasing. At the same time, steady improvement to the standard of care and treatment, and newer breakthroughs in therapeutics, have raised survival rates higher than they've ever been before. But for all too many patients, the question is whether they'll be able to afford those

New findings on cancer survival rates offer hope for the more than 2 million Americans diagnosed each year. Seven out of 10 Americans diagnosed with cancer now survive five years or more, according to the American Cancer Society, a 7 percent increase since the mid-1990s, when the rate stood at 63 percent. The survival rate data - from patients diagnosed with cancer between 2015 and 2021 - showed, significantly, that those with high-mortality cancers and advanced diagnoses had the largest gains.

For years, scientists have viewed cancer as a localized glitch in which cells refuse to stop dividing. But a new study suggests that, in certain organs, tumors actively communicate with the brain to trick it into protecting them. Scientists have long known that nerves grow into some tumors and that tumors containing lots of nerves usually lead to a worse prognosis.

Although specific bacterial taxa have been associated with favourable clinical responses to immune checkpoint blockade (ICB) in cancer patients12,13,18,19,20,21,22, the mechanisms by which the intestinal microbiota influences anti-tumour immune responses remain poorly defined. Products of the microbiota, including metabolites23,24,25 and innate receptor ligands26, may reprogramme myeloid cells27, lowering the activation threshold for antigen presentation and thereby facilitating priming and activation of tumour-reactive T cells.

We knew that if you inject these nanoparticles into an animal model, the nanoparticles get taken up by antigen presenting cells and this resulted in increased regulatory T-cells and decreased inflammatory disease. However, we did not know how this happens,

During viral infection and in the case of cancer, CD4+ helper T-cells release cytokines, or small signaling proteins, that activate and "give permission" to other immune cells to control and clear viral pathogens. In certain viral infections, such as lymphocytic choriomeningitis virus (LCMV), which is spread by infected rodents, CD4+ T-cells differentiate into different subpopulations, including one subset of progenitor CD4+ T-cells that replenish type 1 helper (Th1) and follicular helper (Tfh) T-cells.

When Lisa Dutton was declared free of breast cancer in 2017, she took a moment to celebrate with family and friends, even though she knew her cancer journey might not be over. As many as one-third of people whose breast tumours are cleared see the disease come back, sometimes decades later. Many other cancers are known to recur in the years following an initial treatment, some at much higher rates.

Eduardo Vilar-Sanchez has spent more than 10 years pursuing a goal that seemed very distant, but which he now sees as a little closer: to develop a preventive vaccine against cancer. The physician and researcher is leading a study that presented the first promising results of a colon cancer vaccine in a small group of patients suffering from a rare disease that makes them 17 times more likely to develop colon cancer than the general population.

As for side effects, the companies reported that little had changed from previous analyses; adverse events were similar between the two groups. The top side effects linked to the vaccine were fatigue, injection site pain, and chills. The results "highlight the potential of a prolonged benefit" of the vaccine combined with Keytruda in patients with high-risk melanoma," Kyle Holen, a senior vice president at Moderna, said. They also "illustrate mRNA's potential in cancer care," he said, noting that the company has eight more Phase 2 and Phase 3 trials going for mRNA vaccines against a variety of other cancers, including lung, bladder, and kidney cancers.

The cancer was fastacting, and if I'd left it even six months, the outcome could have been much worse,